Ignite Creation Date:
2025-12-25 @ 5:05 AM
Ignite Modification Date:
2025-12-26 @ 4:08 AM
Study NCT ID:
NCT03651427
Status:
UNKNOWN
Last Update Posted:
2018-08-29
First Post:
2018-08-24
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cross-sex Hormone Therapy and Neuronal Plasticity
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000068116', 'term': 'Gender Dysphoria'}, {'id': 'D007006', 'term': 'Hypogonadism'}], 'ancestors': [{'id': 'D020018', 'term': 'Sexual Dysfunctions, Psychological'}, {'id': 'D001523', 'term': 'Mental Disorders'}, {'id': 'D006058', 'term': 'Gonadal Disorders'}, {'id': 'D004700', 'term': 'Endocrine System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D004958', 'term': 'Estradiol'}], 'ancestors': [{'id': 'D004963', 'term': 'Estrenes'}, {'id': 'D004962', 'term': 'Estranes'}, {'id': 'D013256', 'term': 'Steroids'}, {'id': 'D000072473', 'term': 'Fused-Ring Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D045166', 'term': 'Estradiol Congeners'}, {'id': 'D012739', 'term': 'Gonadal Steroid Hormones'}, {'id': 'D042341', 'term': 'Gonadal Hormones'}, {'id': 'D006728', 'term': 'Hormones'}, {'id': 'D006730', 'term': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}]}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP', 'interventionModelDescription': 'Sel-controlled case series'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 30}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2017-02-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2018-08', 'completionDateStruct': {'date': '2019-03-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2018-08-27', 'studyFirstSubmitDate': '2018-08-24', 'studyFirstSubmitQcDate': '2018-08-27', 'lastUpdatePostDateStruct': {'date': '2018-08-29', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2018-08-29', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-03-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Glutamate concentration in the left hippocampus', 'timeFrame': '90 days', 'description': 'Proton Spectroscopy - magnetic resonance imaging;\n\nGlutamate concentration in the left hippocampus will be primarily correlated to working memory scores.'}], 'secondaryOutcomes': [{'measure': 'Cortical Thickness', 'timeFrame': '90 days', 'description': 'Anatomical magnetic resonance imaging'}, {'measure': 'Diffusion track imaging', 'timeFrame': '90 days', 'description': 'Micro-Structural magnetic resonance imaging'}, {'measure': 'functional connectivity', 'timeFrame': '90 days', 'description': 'functional magnetic resonance imaging'}, {'measure': 'Glutamate concentration in the anterior cingulate cortex and left dorsolateral prefrontal cortex', 'timeFrame': '90 days', 'description': 'Proton spectroscopy - magnetic resonance imaging; Glutamate concentration in the left dorsolateral prefrontal cortex will be correlated to over all measures of cognition and executive functioning.'}, {'measure': 'Cognition', 'timeFrame': '90 days', 'description': 'Instrument: Wechsler Adult Intelligence Scale (WAIS) version 3. Subscale: Full Scale Intelligence coefficient. Mean: 100 Standard deviation (SD):15 for Brazilian population. Range of classification: 69 and below - Extremely Low 70-79 - Borderline 80-89 - Low Average 90-109 - Average 110-119 - High Average 120-129 - Superior 130 and above - very superior'}, {'measure': 'Operational memory', 'timeFrame': '90 days', 'description': 'Subscale from Wechsler Adult Intelligence Scale (WAIS) version 3. Mean: 100 Standard deviation (SD):15 for Brazilian population. 69 and below - Extremely Low 70-79 - Borderline 80-89 - Low Average 90-109 - Average 110-119 - High Average 120-129 - Superior 130 and above - very superior'}, {'measure': 'Verbal memory', 'timeFrame': '90 days', 'description': 'Rey Auditory-Verbal Learning Test (RAVLT). Mean and range for Brazilian population:\n\n1. A1 (Verbal Memory - Immediate recall). Range (in Z-scores): Z \\<-1.5 are classified as deficit; Z \\>-1.5 are expected\n2. A5 (Verbal Memory - immediate recall). Range (in Z-scores): Z \\<-1.5 are classified as deficit; Z \\>-1.5 are expected\n3. A7 (Verbal Memory - late recall). Range in (Z-scores): Z \\<-1.5 are classified as deficit; Z \\>-1.5 are expected\n4. Learning Over Trial (LOT) (Learning capacity). Range (in Z-scores): Z \\<-1.5 are classified as deficit; Z \\>-1.5 are expected (please, note the reference for Brazilian population in the section "references" where the mean and standard deviation according to Brazilian population are described for each of the subtest; Salgado et al. (2011).'}, {'measure': 'Language (Verbal Fluency)', 'timeFrame': '90 days', 'description': 'Verbal Fluency Tests: (FAS) and Animals.\n\nMean and standard deviation (SD) according to age range and years of education:\n\nAge range for the test: 16-59 years\n\nScore classification according to years of education:\n\n1. From 0 to 8 years of education:\n\n Mean: 38.8 SD: 12.0\n2. From 9 to 12 years of education:\n\n Mean: 40.5 SD: 10.7\n3. From 12 to 21 years of education:\n\nMean: 44.7 SD:11.2\n\nRange in Z-scores: Z \\<-1.5 are classified as deficit; Z \\>-1.5 are expected'}, {'measure': 'Executive function', 'timeFrame': '90 days', 'description': 'Stroop Test -Victoria Version.\n\nMean and standard deviation (SD) according to the age range and years of education:\n\nFor 19-39 years old + 5-8 years of education:\n\nMean: 33.3 SD:11.35\n\nFor 19-39 years old + 9 or more years of education:\n\nMean: 41.73 SD: 9.85\n\nFor 40-59 years old + 5-8 years of education:\n\nMean: 28 SD: 7.76\n\nFor 40-59 years old + 9 or more years of education:\n\nMean: 37.17 SD: 9.98\n\nRange in Z-scores:\n\nZ \\<-1.5 are classified as deficit; Z \\>-1.5 are expected'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Estradiol;', 'Brain', 'glutamate', 'spectroscopy', 'hypogonadism'], 'conditions': ['Gender Dysphoria']}, 'referencesModule': {'references': [{'pmid': '21971775', 'type': 'RESULT', 'citation': 'Salgado JV, Malloy-Diniz LF, Abrantes SS, Moreira L, Schlottfeldt CG, Guimaraes W, Freitas DM, Oliveira J, Fuentes D. Applicability of the Rey auditory-verbal learning test to an adult sample in Brazil. Braz J Psychiatry. 2011 Sep;33(3):234-7. doi: 10.1590/s1516-44462011005000007.'}], 'seeAlsoLinks': [{'url': 'http://dx.doi.org/10.1590/S1516-44462011005000007', 'label': 'This references is related to the "verbal memory" evaluation, described in the outcomes.'}]}, 'descriptionModule': {'briefSummary': 'Transgender women (male-to-female) were invited to participate in this study to test the impact of Cross-Sex Hormone Therapy (CSHT) in the brain.\n\nNeuroimaging and cognitive assessment were performed in different time-points to compare the impact of CSHT in the brain.', 'detailedDescription': 'Sex hormones are known to exert several effect on the brain white matter, cerebral cortex, functional connectivity and neurotransmission. Furthermore, in transgender people, CSHT is know to induce anatomical and functional changes in the brain. However, only a few studies have already been conducted to investigate the effects of sex hormones on the brain accounting for the interference of endogenous gonadal hormones. Also, there is a lack of knowledge about the importance of CSHT after Gender Affirming Surgery (GAS) regarding induced hypogonadism that follows this surgical procedure. Therefore, neuroimaging studies designed to isolate the effect of endogenous gonadal hormones in people with GD urge to be developed.\n\nTo fulfil this purpose, transgender women that have already performed GAS and/or were under Gonadotrophin Release Hormone analogues treatment (in order to induce hypogonadism similar to GAS) were invited to interrupt CSHT for at least 30 days to promote sex hormones washout. At the end of the washout, participants performed magnetic resonance imaging, laboratorial analyses for sex hormones and neuro-cognitive assessment. After this first time-point, participants received a new prescription for CSHT containing estradiol (without progesterone) to be used continuously for 60 days, when the same assessments from the end of washout were repeated 60 days after CSHT to compare brain and cognitive longitudinal changes.\n\nAt all the time-points, variations in depression scores and anxiety levels were assessed with specific scales.'}, 'eligibilityModule': {'sex': 'MALE', 'stdAges': ['ADULT'], 'maximumAge': '60 Years', 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Transgender women\n* Age 18 to 60 years old.\n\nExclusion Criteria:\n\n* Use of psychostimulant drugs\n* Use of Antidepressive, Mood Stabiliser, Anti-psychotic, Benzodiazepines, anti-convulsivants, Anorexigenic\n* Endocrinological disease (other than diabetes)\n* Arterial Hypertensive Disease of Diabetes Mellitus out of control target\n* Neurological disease, including stroke or recent cranial trauma with loss or consciousness\n* HIV with low CD4 or high viral charge or symptomatic AIDS\n* Neoplasia'}, 'identificationModule': {'nctId': 'NCT03651427', 'briefTitle': 'Cross-sex Hormone Therapy and Neuronal Plasticity', 'organization': {'class': 'OTHER', 'fullName': 'Hospital de Clinicas de Porto Alegre'}, 'officialTitle': 'Neuroactive Sex Steroids And Their Influence In Glutamatergic Neurotransmission - Effects in Memory and Cognition in Transgender People', 'orgStudyIdInfo': {'id': '150199a'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Transgender Women', 'description': 'Transgender women who already completed GAS or that agreed to start gonadotropin release hormone analogue to suppress endogenous sex hormones.\n\nIf the participants were using CSHT in the moment of the study assignment, they were asked to stop hormones for 30 days to evaluate the impact of hypogonadism in the brain.\n\nAfter this first assessment, they received prescriptions for Estradiol (equine conjugated oestrogen, or estradiol valerate, or topic 17-beta estradiol formulations) for 60 days, and the impact of CSHT was evaluated again to compare to washout condition.', 'interventionNames': ['Drug: Estradiol']}], 'interventions': [{'name': 'Estradiol', 'type': 'DRUG', 'otherNames': ['Drug washout'], 'description': 'Induced hypogonadism and re-institution of CSHT', 'armGroupLabels': ['Transgender Women']}]}, 'contactsLocationsModule': {'locations': [{'zip': '90035-903', 'city': 'Porto Alegre', 'state': 'Rio Grande do Sul', 'status': 'RECRUITING', 'country': 'Brazil', 'contacts': [{'name': 'Maiko Schneider, MD', 'role': 'CONTACT', 'email': 'maikoschneider@hcpa.edu.br', 'phone': '5551997722606'}], 'facility': 'Hospital de Clínicas de Porto Alegre', 'geoPoint': {'lat': -30.03283, 'lon': -51.23019}}], 'centralContacts': [{'name': 'Maiko Schneider, MD', 'role': 'CONTACT', 'email': 'maikoschneider@hcpa.edu.br', 'phone': '5551997722606'}, {'name': 'Fernanda Rohrsetzer', 'role': 'CONTACT', 'email': 'fcunegatto@hcpa.edu.br', 'phone': '51999614503'}], 'overallOfficials': [{'name': 'Maria Lobato, Dr', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Hospital de Clínicas de Porto Alegre'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hospital de Clinicas de Porto Alegre', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}